Careprost (Bimatoprost Ophthalmic 0.03%)
Clinical guidance, bioequivalence criteria, and verified partner dispensing standards for Careprost (Bimatoprost Ophthalmic 0.03%). Reviewed by board-certified internal medicine and clinical pharmacotherapy specialists.
Careprost (Bimatoprost) — Dosage Strengths & Online Availability
| Dosage Strength | Pack Supply | Dispensary Price | Stock Status | Verified Order |
|---|---|---|---|---|
| Careprost 0.03% (3mL) POPULAR | Ophthalmic Solution + Applicators • 30 / 60 Units | $2.38 / unit | ✓ In Stock (US Dispatch) | Select & Check Price ↗ |
1. Clinical Dosing & Titration Protocols
Daily / Baseline Regimen
Apply one single drop along upper eyelid margin at eyelash base once nightly.
On-Demand / Titration Regimen
Nightly application for 12–16 weeks.
Do not apply directly inside eyes or to lower eyelid.
2. Patient Administration & Safe Usage Guidelines
Remove contact lenses before application. Apply strictly to upper eyelid base.
Verified Telehealth Access Standards for Careprost (Bimatoprost Ophthalmic 0.03%)
Our clinical editorial board audits certified partner telehealth dispensaries to guarantee authentic WHO-GMP manufacturing, analytical batch testing, and physician-supervised asynchronous consultation.
Check Telehealth Protocol & Availability ↗3. Frequently Asked Patient Questions
How does Careprost compare to Allergan Latisse?
Careprost contains identical Bimatoprost 0.03% in sterile isotonic solution, offering bioequivalent results at 80% lower cost.
When are full eyelash results visible?
Initial growth starts at week 4; full length, density, and darkness peak at week 16.
4. Pharmacological Mechanism & Receptor Profile
Synthetic prostamide analog clinically proven to extend eyelash follicle growth phase (anagen), increasing lash length, thickness, and dark pigmentation.
Dermatology & Retinoids • Careprost (Bimatoprost Ophthalmic 0.03%)
5. Chemical & Human Pharmacokinetic Matrix (Tmax, Half-Life, CYP450)
| Pharmacokinetic Parameter | Clinical Metric | Therapeutic Significance |
|---|---|---|
| Peak Plasma Time (Tmax) | Local dermal follicular transit | Determines latency from ingestion to peak pharmacological onset. |
| Elimination Half-Life (T½) | 45 minutes systemic clearance | Governs duration of action and steady-state dosing intervals. |
| Peak Concentration (Cmax) | <0.1 ng/mL | Maximum observed systemic concentration in human plasma. |
| Bioavailability & Food Interaction | Negligible systemic transit | Defines oral bioavailability and dietary lipid dependency. |
| Plasma Protein Binding | 88% | Governs free circulating drug fraction available for receptor binding. |
| Volume of Distribution (Vd) | 0.67 L/kg | Reflects tissue and lipid compartment penetration. |
| Hepatic Metabolism | Hydrolysis to active free acid | Primary enzymatic clearance and CYP pathways. |
| Elimination / Excretion | 67% urine, 25% feces | Renal vs biliary/fecal excretion balance. |
6. Drug-Drug Interaction Matrix
| Interacting Agent / Class | Severity Tier | Clinical Mechanism & Management Strategy |
|---|---|---|
| Prostaglandin Eyedrops | Precaution | May alter intraocular pressure in glaucoma. |
7. Adverse Reaction Profile & Clinical Incidence Rates
| Adverse Reaction | Incidence Rate | Physiological Mechanism & Mitigation Strategy |
|---|---|---|
| Conjunctival Redness | 4% | If solution enters eye. |
| Eyelid Margin Darkening | 2% | Reversible pigmentation. |
Peer-Reviewed Scientific Citations & FDA References
- Fagien S, et al. Bimatoprost 0.03% for eyelash growth. Aesthet Surg J. 2013;33(5):738-745.